China Meheco Group Co Ltd signed an agreement with Pfizer Inc to supply the latter’s COVID-19 treatment Paxlovid in the Chinese mainland in 2022, the company said Wednesday.
The move marks China Meheco becoming the domestic agent of the new COVID-19 pill. Pfizer also confirmed the news on its official website.
The agreement details delivery, payments, quality guarantee and assessment, contract termination and dispute resolution. However, prices and sales commissions are not disclosed.
Listed on the Shanghai Stock Exchange, China Meheco is a holding company under China General Technology (Group) Holding Co Ltd (Genertec), one of China’s centrally administered State-owned enterprises. Its core businesses are the medical industry, pharmaceuticals and international trade. The company recorded revenue of 31 billion yuan, 35.29 billion yuan, and 39.31 billion yuan in 2018, 2019, and 2020, respectively, with a net profit of 1.55 billion yuan, 981 million yuan, and 1.31 billion yuan during the same period.
As previously reported on PharmProm, in February, the National Medical Products Administration, China’s top drug regulator, gave conditional approval for Pfizer’s COVID-19 treatment Paxlovid, making it the first oral pill for the disease approved in the country.
The drug can be used to treat adults who have mild to moderate symptoms and a high risk of progressing to more severe diseases. These patients include the elderly and people with chronic kidney or lung issues, cardiovascular disease, diabetes and other high-risk factors.
Currently, Paxlovid is authorized for emergency use and has been granted conditional marketing approval in about 40 countries, including the United States, the United Kingdom, Canada, Israel, Germany, Belgium, South Korea, Singapore, and Japan.